Sign In
Buy ABT
$90.53
+2.76 (+3.14%)
At Close: Jun 23, 2026
Why This Healthcare Giant Expects Decreased Covid Profits in 2022
11:30am, Friday, 11'th Feb 2022 The Motley Fool
Abbott may soon be returning to its pre-pandemic days.
Why This Healthcare Giant Expects Decreased Covid Profits in 2022
06:30am, Friday, 11'th Feb 2022
Abbott may soon be returning to its pre-pandemic days.
Here's Why You Should Retain Abbott (ABT) Stock For Now
03:44pm, Thursday, 10'th Feb 2022 Zacks Investment Research
Investors continue to be optimistic about Abbott (ABT) owing to the strength in its diagnostics business.
The Vanguard Health Care Fund's Top 5 Trades
12:52pm, Thursday, 10'th Feb 2022
The Vanguard Health Care Fund (Trades, Portfolio) released its fourth-quarter 2021 portfolio earlier this week.
Here's Why You Should Retain Abbott (ABT) Stock For Now
12:19pm, Thursday, 10'th Feb 2022
Investors continue to be optimistic about Abbott (ABT) owing to the strength in its diagnostics business.
My Best Dividend Kings For February 2022
03:46am, Wednesday, 09'th Feb 2022
The 36 Dividend Kings started 2022 on a sour note losing 3.88% during January. The 8 best dividend kings based on forecasted growth and valuation trailed the average dividend king return by 129 bps in
Diamond Hill Capital Makes New Tech Bets, Sells Charles Schwab
05:28pm, Tuesday, 08'th Feb 2022
Diamond Hill Capital (Trades, Portfolio) recently disclosed its 13F portfolio updates for the fourth quarter of 2021, which ended on Dec. 31.
3 Top Healthcare Stocks to Buy for February
04:15pm, Tuesday, 08'th Feb 2022 The Motley Fool
Whether you're looking for growth or big dividends, the healthcare sector's got deals galore.
3 Medical Products Stocks Poised to Beat This Earnings Season
02:49pm, Monday, 07'th Feb 2022 Zacks Investment Research
The Medical Products companies' Q4 results are likely to reflect base business recovery. Let's see how BAX, HSIC, and XRAY are poised ahead of their earnings releases.
AbbVie Wins Yet Another Approval for This Drug
12:59pm, Monday, 07'th Feb 2022 The Motley Fool
Rinvoq was recently authorized in the U.S. as a treatment for patients with moderate-to-severe eczema.
3 Medical Products Stocks Poised to Beat This Earnings Season
11:34am, Monday, 07'th Feb 2022
The Medical Products companies' Q4 results are likely to reflect base business recovery. Let's see how BAX, HSIC, and XRAY are poised ahead of their earnings releases.
Abbott Stock is an Oversold Play
06:01am, Monday, 07'th Feb 2022
Diversified global medical science products maker Abbott (NYSE: ABT) stock has sold off with the benchmark indexes in a throw the baby out with the bath water type reaction.
The Coming Sell-Off May Be Huge: 5 Dividend Aristocrats to Buy Now for Safety and Income
07:34am, Friday, 04'th Feb 2022
It was nice while it lasted, but the dumpster fire that was the quarterly earnings report from Meta Platforms (known for years as Facebook) may have lit the fuse for a continuation of the selling we s
Were Hedge Funds Right About Abbott Laboratories (ABT)?
04:10pm, Wednesday, 02'nd Feb 2022 Insider Monkey
The latest 13F reporting period has come and gone, and Insider Monkey is again at the forefront when it comes to making use of this gold mine of data.
Abbott's (ABT) Diabetes Arm Booms, Neuromodulation Sales Soft
01:04pm, Wednesday, 02'nd Feb 2022
Even though COVID-19 case rates are surging in the United States and other geographies, Abbott is seeing growth in its consumer-facing businesses like nutrition, EPD and diabetes care.
